The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy
Abstract
PURPOSE: To assess the efficacy of Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, in thyroid eye disease patients refractory to multiple intravenous steroids. METHODS: Prospective interventional nonrandomized study including active GO defined by Clinical Activity Score (CAS) ≥4 patients resistant to previous intravenous steroids treated with Tocilizumab was conducted from February 2010 to September 2012. Snellen visual acuity, Hertel exophthalmometry, CAS evaluation, TSI levels, ocular motility, and side effects were registered at a 4-week interval. RESULTS: Eighteen patients were included with a mean age of 47.9 ± 8.63 years. All patients had a significant progressive CAS improvement (mean CAS score reduction 5.89 ± 1.41 points, p< 0.00027). Mean TSI levels were significantly lower at the end of the treatment (mean -76.18% ± 17.80%, p = 0.00007). Thirteen patients (72.22%) reduced proptosis a mean of -3.92 ± 1.54 mm (p = 0.002). Fifteen patients (83.33%) had an improvement in extraocular motility, and 7 patients of 13 resolved their diplopia (53.85%). No severe side effects or relapse of active GO were observed at the end of follow up. CONCLUSIONS: This study suggests that intravenous Tocilizumab may be effective on reducing activity in patients with thyroid eye disease refractory to intravenous steroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Cited by
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Davies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
Taylor, P. N., Zhang, L., Lee, R. W. J., Muller, I., Ezra, D. G., Dayan, C. M., Kahaly, G. J., & Ludgate, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0305-4 · Cited by 315
Perez-Moreiras, J. V., Gomez-Reino, J. J., Maneiro, J. R., Perez-Pampin, E., Romo Lopez, A., Rodríguez Alvarez, F. M., Castillo Laguarta, J. M., del Estad Cabello, A., Gessa Sorroche, M., España Gregori, E., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.038 · Cited by 300
Extrathyroidal manifestations of Graves’ disease: a 2014 update
Bartalena, L., & Fatourechi, V. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0097-2 · Cited by 279
Metadata
- Authors
- Pérez-Moreiras, J. V., Álvarez-López, A., & Gómez, E. C.
- Venue
- Ophthalmic Plastic & Reconstructive Surgery
- Published
- 2014-03
- Volume
- 30
- Issue
- 2
- Pages
- 162-167
- ISSN
- 0740-9303 (ISSN-L)
- OpenAlex
- W2083681450
- Cited by
- 198
- References
- 2
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy. https://app.cochat.ai/papers/10.1097/iop.0000000000000037
- The paper
- Pérez-Moreiras, J. V., Álvarez-López, A., & Gómez, E. C. (2014). Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy. Ophthalmic Plastic & Reconstructive Surgery. https://doi.org/10.1097/iop.0000000000000037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.